{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:10:25Z","timestamp":1772118625593,"version":"3.50.1"},"reference-count":70,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["PEJ\u20102018\u2010TL\/BMD\u201011080"],"award-info":[{"award-number":["PEJ\u20102018\u2010TL\/BMD\u201011080"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess adverse events (AEs) and safety of aripiprazole (ARI) and olanzapine (OLA) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty\u2010four healthy volunteers receiving five daily oral doses of 10 mg ARI and 5 mg OLA in a crossover clinical trial were genotyped for 46 polymorphisms in 14 genes by qPCR. Drug plasma concentrations were measured by high\u2010performance liquid chromatography tandem mass spectrometry. Blood pressure (BP) and 12\u2010lead electrocardiogram were measured in supine position. AEs were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ARI decreased diastolic BP on the first day and decreased QTc on the third and fifth day. OLA had a systolic and diastolic BP, heart rate and QTc lowering effect on the first day. Polymorphisms in\n                      <jats:italic>ADRA2A<\/jats:italic>\n                      ,\n                      <jats:italic>COMT<\/jats:italic>\n                      ,\n                      <jats:italic>DRD3<\/jats:italic>\n                      and\n                      <jats:italic>HTR2A<\/jats:italic>\n                      genes were significantly associated to these changes. The most frequent adverse drug reactions (ADRs) to ARI were somnolence, headache, insomnia, dizziness, restlessness, palpitations, akathisia and nausea while were somnolence, dizziness, asthenia, constipation, dry mouth, headache and nausea to OLA. Additionally,\n                      <jats:italic>HTR2A<\/jats:italic>\n                      ,\n                      <jats:italic>HTR2C<\/jats:italic>\n                      ,\n                      <jats:italic>DRD2<\/jats:italic>\n                      ,\n                      <jats:italic>DRD3<\/jats:italic>\n                      ,\n                      <jats:italic>OPRM1<\/jats:italic>\n                      ,\n                      <jats:italic>UGT1A1<\/jats:italic>\n                      and\n                      <jats:italic>CYP1A2<\/jats:italic>\n                      polymorphisms had a role in the development of ADRs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OLA induced more cardiovascular changes; however, more ADRs were registered to ARI. In addition, some polymorphisms may explain the difference in the incidence of these effects among subjects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hup.2761","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T18:03:45Z","timestamp":1601402625000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and cardiovascular effects of multiple\u2010dose administration of aripiprazole and olanzapine in a randomised clinical trial"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-0466","authenticated-orcid":false,"given":"Dora","family":"Koller","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Almenara","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-7941","authenticated-orcid":false,"given":"Gina","family":"Mej\u00eda","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"},{"name":"UICEC Hospital Universitario de La Princesa Platform SCReN (Spanish Clinical Research Network) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-3135","authenticated-orcid":false,"given":"Miriam","family":"Saiz\u2010Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"},{"name":"Research Unit Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud Hospital Universitario de Burgos  Burgos Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-4320","authenticated-orcid":false,"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"},{"name":"UICEC Hospital Universitario de La Princesa Platform SCReN (Spanish Clinical Research Network) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"},{"name":"UICEC Hospital Universitario de La Princesa Platform SCReN (Spanish Clinical Research Network) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Wojnicz","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"},{"name":"UICEC Hospital Universitario de La Princesa Platform SCReN (Spanish Clinical Research Network) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Romero\u2010Palaci\u00e1n","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-6845","authenticated-orcid":false,"given":"Marcos","family":"Navares\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad\u2010Santos","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando School of Medicine, Universidad Aut\u00f3noma de Madrid Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"},{"name":"UICEC Hospital Universitario de La Princesa Platform SCReN (Spanish Clinical Research Network) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"e_1_2_11_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.06.012"},{"key":"e_1_2_11_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0594.2010.00588.x"},{"key":"e_1_2_11_1_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.67"},{"key":"e_1_2_11_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01588.x"},{"key":"e_1_2_11_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-474X.1997.tb00325.x"},{"key":"e_1_2_11_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"e_1_2_11_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000577"},{"key":"e_1_2_11_1_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.10.1003"},{"key":"e_1_2_11_1_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161010-00011"},{"key":"e_1_2_11_1_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_2_11_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"e_1_2_11_1_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2308"},{"key":"e_1_2_11_1_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00001"},{"key":"e_1_2_11_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12692"},{"key":"e_1_2_11_1_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-012-9233-3"},{"issue":"1","key":"e_1_2_11_1_17_1","first-page":"51","article-title":"Second\u2010generation antipsychotics for schizophrenia: A review of clinical pharmacology and medication\u2010associated side effects","volume":"42","author":"Conley R. R.","year":"2005","journal-title":"The Israel Journal of Psychiatry and Related Sciences"},{"issue":"8","key":"e_1_2_11_1_18_1","first-page":"26","article-title":"Adverse events related to olanzapine","volume":"61","author":"Conley R. R.","year":"2000","journal-title":"The Journal of Clinical Psychiatry"},{"key":"e_1_2_11_1_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0310"},{"key":"e_1_2_11_1_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.3.1.9"},{"key":"e_1_2_11_1_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0352-5"},{"key":"e_1_2_11_1_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100406"},{"issue":"11","key":"e_1_2_11_1_23_1","first-page":"15055","article-title":"COMT Val158Met polymorphism is associated with blood pressure and lipid levels in general families of Bama longevous area in China","volume":"8","author":"Ge L.","year":"2015","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"e_1_2_11_1_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.11.1774"},{"key":"e_1_2_11_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.05.023"},{"key":"e_1_2_11_1_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000213"},{"key":"e_1_2_11_1_27_1","doi-asserted-by":"publisher","DOI":"10.3371\/1935-1232-11.1.39"},{"key":"e_1_2_11_1_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2011.93"},{"key":"e_1_2_11_1_29_1","unstructured":"International Council on Harmonisation. (2005).The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. European Medicines Agency (EMA). CHMP\/ICH\/2\/04."},{"key":"e_1_2_11_1_30_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900026201"},{"key":"e_1_2_11_1_31_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2015.13.1.113"},{"key":"e_1_2_11_1_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/273060"},{"key":"e_1_2_11_1_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03223.x"},{"key":"e_1_2_11_1_34_1","article-title":"Metabolic effects of aripiprazole and olanzapine multiple\u2010dose treatment in healthy volunteers","author":"Koller D.","year":"2020","journal-title":"Association with Pharmacogenetics"},{"key":"e_1_2_11_1_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14300"},{"key":"e_1_2_11_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2019.01.112"},{"key":"e_1_2_11_1_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.110.957662"},{"key":"e_1_2_11_1_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00777.x"},{"key":"e_1_2_11_1_39_1","doi-asserted-by":"publisher","DOI":"10.2190\/U99G-XDML-0GRG-BYE0"},{"key":"e_1_2_11_1_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0056-x"},{"key":"e_1_2_11_1_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"e_1_2_11_1_42_1","doi-asserted-by":"publisher","DOI":"10.1590\/0101-60830000000125"},{"issue":"2","key":"e_1_2_11_1_43_1","first-page":"146","article-title":"The effect of gender on heart rate variability in asthmatic and normal healthy adults","volume":"5","author":"Lutfi M. F.","year":"2011","journal-title":"International Journal of Health Sciences"},{"key":"e_1_2_11_1_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270002042001013"},{"key":"e_1_2_11_1_45_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2016.264986"},{"key":"e_1_2_11_1_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/03630240802100051"},{"key":"e_1_2_11_1_47_1","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.5256"},{"key":"e_1_2_11_1_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4024-9"},{"key":"e_1_2_11_1_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5920.656"},{"key":"e_1_2_11_1_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806994"},{"key":"e_1_2_11_1_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2498-1"},{"key":"e_1_2_11_1_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119827959"},{"key":"e_1_2_11_1_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13141"},{"key":"e_1_2_11_1_54_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.116.053736"},{"key":"e_1_2_11_1_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn023"},{"key":"e_1_2_11_1_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00191.x"},{"key":"e_1_2_11_1_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"key":"e_1_2_11_1_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2323-2"},{"key":"e_1_2_11_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.10.024"},{"key":"e_1_2_11_1_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199922"},{"key":"e_1_2_11_1_61_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666150115220221"},{"key":"e_1_2_11_1_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2008.01833.x"},{"issue":"10","key":"e_1_2_11_1_63_1","first-page":"1245","article-title":"Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta\u2010analysis","volume":"159","author":"Trindade E.","year":"1998","journal-title":"CMAJ: Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne"},{"key":"e_1_2_11_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381326-8.00002-8"},{"key":"e_1_2_11_1_65_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v05n0504"},{"key":"e_1_2_11_1_66_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.1857"},{"key":"e_1_2_11_1_67_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.12030046"},{"key":"e_1_2_11_1_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4950250203"},{"key":"e_1_2_11_1_69_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S43950"},{"key":"e_1_2_11_1_70_1","doi-asserted-by":"publisher","DOI":"10.4306\/pi.2016.13.2.232"},{"key":"e_1_2_11_1_71_1","volume-title":"ZYPREXA (olanzapine). Highlights of prescribing information","author":"ZYPREXA (olanzapine), FDA","year":"1996"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2761","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hup.2761","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T06:11:42Z","timestamp":1693721502000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1002\/hup.2761"],"URL":"https:\/\/doi.org\/10.1002\/hup.2761","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.03.20167502","asserted-by":"object"}]},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"2020-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}